Biodexa Pharmaceuticals Statistics
Total Valuation
BDRX has a market cap or net worth of $2.14 million. The enterprise value is -$9.23 million.
Important Dates
The last earnings date was Friday, September 12, 2025, before market open.
| Earnings Date | Sep 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BDRX has 648,313 shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 648,313 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +234.24% |
| Owned by Insiders (%) | 0.43% |
| Owned by Institutions (%) | 1.34% |
| Float | 550,717 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.10 |
| P/TBV Ratio | 0.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.03, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.03 |
| Quick Ratio | 1.43 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -37.75 |
Financial Efficiency
Return on equity (ROE) is -64.72% and return on invested capital (ROIC) is -294.85%.
| Return on Equity (ROE) | -64.72% |
| Return on Assets (ROA) | -32.79% |
| Return on Invested Capital (ROIC) | -294.85% |
| Return on Capital Employed (ROCE) | -71.74% |
| Weighted Average Cost of Capital (WACC) | 20.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$781,109 |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -141,319 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.74% in the last 52 weeks. The beta is 1.11, so BDRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -95.74% |
| 50-Day Moving Average | 4.16 |
| 200-Day Moving Average | 21.32 |
| Relative Strength Index (RSI) | 42.26 |
| Average Volume (20 Days) | 1,324,488 |
Short Selling Information
The latest short interest is 40,924, so 6.31% of the outstanding shares have been sold short.
| Short Interest | 40,924 |
| Short Previous Month | 7,530 |
| Short % of Shares Out | 6.31% |
| Short % of Float | 7.43% |
| Short Ratio (days to cover) | 0.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | -5.33M |
| Operating Income | -11.64M |
| Pretax Income | -8.73M |
| Net Income | -8.59M |
| EBITDA | -11.57M |
| EBIT | -11.64M |
| Earnings Per Share (EPS) | -$78.31 |
Full Income StatementBalance Sheet
The company has $11.49 million in cash and $82,100 in debt, giving a net cash position of $11.40 million or $17.59 per share.
| Cash & Cash Equivalents | 11.49M |
| Total Debt | 82,100 |
| Net Cash | 11.40M |
| Net Cash Per Share | $17.59 |
| Equity (Book Value) | 15.35M |
| Book Value Per Share | 33.99 |
| Working Capital | 8.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.52 million and capital expenditures -$2,692, giving a free cash flow of -$7.55 million.
| Operating Cash Flow | -7.52M |
| Capital Expenditures | -2,692 |
| Depreciation & Amortization | 70,188 |
| Net Borrowing | -939,437 |
| Free Cash Flow | -7.55M |
| FCF Per Share | -$11.64 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |